Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Progressive Metastatic Prostate Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Study completedNCT01303705
What this trial is testing

Anti-OX40, Cyclophosphamide (CTX) and Radiation in Patients With Progressive Metastatic Prostate Cancer

Who this might be right for
Metastatic Prostate CancerCancer of the ProstateProstate Cancer
Providence Health & Services 13
Post-approval studies (Phase 4)Active Not RecruitingNCT04597125
What this trial is testing

RADIANT: A Study of Radium-223 Dichloride (Xofigo) vs Enzalutamide or Abiraterone (ARPIs, Androgen Receptor Pathway Inhibitors) in Patients With Prostate Cancer That Has Spread to the Bones (mCRPC, Metastatic Castration-Resistant Prostate Cancer)

Who this might be right for
Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Bayer 654
Testing effectiveness (Phase 2)Study completedNCT03392428
What this trial is testing

A Trial of 177Lu-PSMA617 Theranostic Versus Cabazitaxel in Progressive Metastatic Castration Resistant Prostate Cancer

Who this might be right for
Cancer of the ProstateMetastatic Cancer
Australian and New Zealand Urogenital and Prostate Cancer Trials Group 201
Testing effectiveness (Phase 2)Study completedNCT01677897
What this trial is testing

Impact of the Addition of Metformin to Abiraterone in Metastatic Prostate Cancer Patients

Who this might be right for
Metastatic Prostate Cancer
Kantonsspital Graubünden 25
Testing effectiveness (Phase 2)Looking for participantsNCT07567521
What this trial is testing

TRC003 in the Treatment of Patients With Progressive PSMA-positive mCRPC

Who this might be right for
Prostate Cancer
C Ray Therapeutics 90
Testing effectiveness (Phase 2)Study completedNCT01171898
What this trial is testing

Safety, Pharmacokinetic and Proof-of-Concept Study of ARN-509 (Apalutamide) in Castration-Resistant Prostate Cancer (CRPC)

Who this might be right for
Prostate Cancer
Aragon Pharmaceuticals, Inc. 127
Large-scale testing (Phase 3)UnknownNCT04139772
What this trial is testing

Docetaxel or Hormone Therapy as Second Line Treatment in Patients With Asymptomatic or Oligosymptomatic Metastatic Castration-resistent Prostate Cancer (mCRPC) Progressing After Abiraterone or Enzalutamide.

Who this might be right for
Metastatic Castration-resistent Prostate Cancer
National Cancer Institute, Naples 18
Testing effectiveness (Phase 2)Ended earlyNCT00080782
What this trial is testing

Doxorubicin and Strontium-89 With or Without Celecoxib in Treating Patients With Progressive Androgen-Independent Prostate Cancer and Bone Metastases

Who this might be right for
Metastatic CancerProstate Cancer
M.D. Anderson Cancer Center 14
Large-scale testing (Phase 3)Study completedNCT00538850
What this trial is testing

Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain

Who this might be right for
Cancer
INSYS Therapeutics Inc 130
Early research (Phase 1)Study completedNCT02106507
What this trial is testing

ARN 509 Plus Everolimus in Men With Progressive Metastatic Castration-Resistant Prostate Cancer After Treatment With Abiraterone Acetate

Who this might be right for
Prostate Cancer
Memorial Sloan Kettering Cancer Center 9
Testing effectiveness (Phase 2)Active Not RecruitingNCT06894511
What this trial is testing

An Open-label Study of Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI Versus AAA617 in PSMA Positive First-line mCRPC

Who this might be right for
Metastatic Castration Resistant Prostate Cancer (mCRPC)
Novartis Pharmaceuticals 7
Testing effectiveness (Phase 2)Study completedNCT03939689
What this trial is testing

I-131-1095 Radioligand Plus Enzalutamide vs Enzalutamide for mCRPC That Progressed During Abiraterone (ARROW).

Who this might be right for
Metastatic Prostate CancerCastration-resistant Prostate CancerProstatic Neoplasm+2 more
Progenics Pharmaceuticals, Inc. 120
Testing effectiveness (Phase 2)Active Not RecruitingNCT01688492
What this trial is testing

Combining Ipilimumab With Abiraterone Acetate Plus Prednisone in Chemotherapy and Immunotherapy-naïve Patients With Progressive Metastatic Castration-resistant Prostate Cancer

Who this might be right for
Prostate Cancer
Memorial Sloan Kettering Cancer Center 54
Not applicableNo Longer AvailableNCT03386071
What this trial is testing

Compassionate Use: Progressive Metastatic Castrate Resistant Prostate Cancer; Monotherapy Treatment With Trametinib

Who this might be right for
Progressive Metastatic Castrate Resistant Prostate Cancer
Jonsson Comprehensive Cancer Center
Early research (Phase 1)Looking for participantsNCT07641049
What this trial is testing

Dual-target PSMA/PSCA CAR-NK Cells in Advanced Prostate Cancer

Who this might be right for
Metastatic Castration-resistant Prostate CancerAdvanced Prostate AdenocarcinomaPSCA-positive Prostate Cancer+1 more
Beijing Biotech 36
Testing effectiveness (Phase 2)Study completedNCT02445976
What this trial is testing

Once-daily Oral Seviteronel in Patients With Castration-Resistant Prostate Cancer Progressing on Enzalutamide or Abiraterone.

Who this might be right for
Prostate Cancer
Innocrin Pharmaceutical 197
Testing effectiveness (Phase 2)Looking for participantsNCT04946370
What this trial is testing

Phase I/II Trial of Pembrolizumab and Androgen-receptor Inhibitor With or Without 225Ac-J591 for Progressive Metastatic Castration Resistant Prostate Cancer

Who this might be right for
Prostate Cancer
Weill Medical College of Cornell University 52
Not applicableLooking for participantsNCT07538843
What this trial is testing

An Observational Study Conducted in China to Evaluate the Efficacy and Safety of Darolutamide in Combination With Androgen Deprivation Therapy (ADT) for Men With Non-metastatic Prostate Cancer That Progressed Following Prior Bicalutamide + ADT Treatment

Who this might be right for
Non-metastatic Castration-resistant Prostate Cancer
Bayer 800
Testing effectiveness (Phase 2)Active Not RecruitingNCT05658003
What this trial is testing

A Study Evaluating [177Lu]Lu-PSMA-617 vs. a Change of Androgen Receptor-directed Therapy in Taxane Treatment Naive Chinese Male Patients With Progressive Metastatic Castrate Resistant Prostate Cancer

Who this might be right for
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Novartis Pharmaceuticals 63
Early research (Phase 1)Ended earlyNCT03490838
What this trial is testing

177Lu-PSMA-R2 in Patients With PSMA Positive Progressive, Metastatic, Castration Resistant Prostate Cancer

Who this might be right for
Prostatic Neoplasm
Advanced Accelerator Applications 27
Next Page